Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its financial expectations.

Bristol Myers Squibb will cease production of viral vectors from its plant in Libertyville, Illinois, the company has told Fierce Pharma. The facility, which was previously used by Novartis to manufacture the gene therapy Zolgensma, was picked up by BMS in early 2023 to bolster viral vector capacity for its commercial cell therapy portfolio.

To REMS, or not to REMS. That, apparently, was the question for Cytokinetics, which has seen any potential approval for its experimental heart drug delayed by an extra three months over an unusual safety program omission and addition.

HistoSonics is shopping for a potential buyer of its approach to destroying liver tumors with focused sound waves, according to the Financial Times.

This year's 24 Hours of Le Mans endurance car race in France in June will see a United Autosports McLaren clad with a Sanofi-created meningitis awareness flag in a campaign meant to illustrate how "every second counts" when it comes to meningitis.

While Amgen’s legacy products are thriving, those gained from the company’s $27.8 billion buyout of Horizon Therapeutics in 2023 are struggling, especially blockbuster eye disease treatment Tepezza, which saw a 17% sequential decline in the first quarter.

The National Institutes of Health is making a major change to how grant recipients can use their funds. The agency plans to end the subaward process that has been under increased scrutiny since the beginning of the COVID-19 pandemic.

Far from doffing their caps to actinic keratosis (AK), dermatology drug developers Almirall and Biofrontera are keeping things firmly covered to raise awareness of the skin cancer precursor.

Eighteen years ago, Tim Friede began willingly injecting himself with escalating doses of venom from 16 snake species. Now, antibodies in his blood have led to the development of a three-part antivenom cocktail capable of protecting mice from the toxins of 19 dangerous snakes.

Reductions in staff at the FDA are putting pressure on biotech companies, especially those strapped for cash, and could lead to more M&A activity, according to Andrew Goodman, a partner in the M&A practice at business law firm Paul Hastings.

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants.

Scholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal muscular atrophy drug apitegromab later this year. CEO Jay Backstrom, M.D., is stepping down, making room for longtime board chairman David Hallal to take over. Hallal previously spent more than a decade in C-suite roles at what is now AstraZeneca’s Alexion, culminating in nearly two years as CEO.